Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Inclusion Criteria: * Male or female subjects ages 21 to 75 inclusive. Female subjects must be of non-childbearing potential; * Has at the Screening Visit a serum uric acid ≥ 6 mg/dL, with or without a history of gout; * The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering therapy is permissible if dosing has been stable for at least the month prior to the Screening Visit * Has adequate venous access and able to receive IV therapy; * Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study; Exclusion Criteria: * Prior exposure to any experimental or marketed uricase; * History of any allergy to pegylated products, * Glucose-6-phosphate dehydrogenase deficiency or known catalase deficiency; * History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised; * Has participated in a clinical trial within 30 days of the Screening;